BMY:NYE-Bristol-Myers Squibb Company (USD)

COMMON STOCK | Drug Manufacturers-General | NYE

Last Closing Price

USD 64.68

Change

+0.73 (+1.14)%

Market Cap

USD 142.79B

Volume

0.01B

Average Target Price

USD 72.20 (+11.63%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
JNJ Johnson & Johnson

-0.70 (-0.42%)

USD441.81B 29.64 26.08
PFE Pfizer Inc

+0.02 (+0.05%)

USD222.85B 23.40 18.09
ABBV AbbVie Inc

+1.88 (+1.65%)

USD201.01B 39.10 41.07
NVS Novartis AG

+0.87 (+1.02%)

USD193.15B 24.82 13.09
MRK Merck & Co., Inc

+1.71 (+2.25%)

USD192.35B 27.44 23.90
LLY Eli Lilly and Company

+4.61 (+2.45%)

USD181.27B 28.28 25.07
SNYNF Sanofi

N/A

USD130.20B 8.98 8.98
GSK GlaxoSmithKline plc

+0.28 (+0.75%)

USD93.74B 13.02 12.32
AGN Allergan plc

N/A

USD63.66B 22.00 28.44

ETFs Containing BMY

Symbol Name Weight Mer Price(Change) Market Cap
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

-0.23 (-0.78%)

USD0.05B
UC98:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.20 %

-2.25 (-0.17%)

USD0.29B
LOWV:LSE SPDR® S&P 500 Low Volati.. 0.00 % 0.35 %

-0.07 (-0.11%)

USD0.23B
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.65 %

-53.00 (-0.27%)

USD0.08B
UC76:LSE UBS(Lux)Fund Solutions &#.. 0.00 % 0.18 %

-0.01 (-0.03%)

USD0.12B
UC82:LSE UBS(Lux)Fund Solutions &#.. 0.00 % 0.23 %

+2.54 (+0.18%)

USD0.06B
UC84:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.00 %

N/A

USD0.12B
UC85:LSE UBS(Lux)Fund Solutions &#.. 0.00 % 0.23 %

+0.40 (+0.02%)

USD0.08B
UC86:LSE UBS(Lux)Fund Solutions &#.. 0.00 % 0.18 %

N/A

USD0.32B
UC97:LSE UBS(Lux)Fund Solutions &#.. 0.00 % 0.20 %

+0.01 (+0.03%)

USD0.29B
USLV:LSE SPDR S&P 500 Low Vola.. 0.00 % 0.35 %

-0.12 (-0.25%)

USD0.26B
DGRG:LSE WisdomTree Issuer ICAV - .. 0.00 % 0.33 %

N/A

USD0.07B
USMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.65 %

N/A

N/A
MVUS:PA Ossiam US Minimum Varianc.. 0.00 % 0.65 %

-0.55 (-0.20%)

N/A
SPMV:PA Ossiam US Minimum Varianc.. 0.00 % 0.65 %

-0.21 (-0.09%)

N/A
ETLI:F L&G Pharma Breakthrou.. 0.00 % 0.49 %

+0.09 (+0.88%)

USD0.03B
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.65 %

-0.30 (-0.13%)

N/A
ETLI:XETRA L&G Pharma Breakthrou.. 0.00 % 0.49 %

+0.07 (+0.70%)

USD0.03B
OSX2:XETRA Ossiam US Minimum Varianc.. 0.00 % 0.65 %

-0.15 (-0.07%)

N/A
SPY1:XETRA SPDR S&P 500 Low Volatili.. 0.00 % 0.35 %

+0.08 (+0.15%)

USD0.22B
UET0:XETRA UBS ETF - Bloomberg Barcl.. 0.00 % 0.00 %

-0.02 (-0.09%)

USD0.53B
DGRP:LSE WisdomTree US Quality Div.. 0.00 % 0.33 %

+16.50 (+0.76%)

USD0.07B
BSUS:LSE UBS(Lux)Fund Solutions &#.. 0.00 % 0.25 %

+0.50 (+0.05%)

USD0.25M
CORP PIMCO Investment Grade Co.. 0.00 % 0.20 %

+0.17 (+0.15%)

USD0.77B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.04 (-0.53%)

USD1.42M
GBF iShares Government/Credit.. 0.00 % 0.20 %

+0.09 (+0.07%)

USD0.28B
IBDP iShares iBonds Dec 2024 T.. 0.00 % 0.10 %

+0.01 (+0.04%)

USD1.26B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

+0.79 (+0.44%)

USD0.36B
JHMH John Hancock Multifactor .. 0.00 % 0.40 %

-0.11 (-0.24%)

USD0.05B
LNGR Global X Aging Population.. 0.00 % 0.50 %

N/A

USD0.04B
PILL Direxion Daily Pharmaceut.. 0.00 % 1.00 %

+0.25 (+1.29%)

USD0.01B
PPH VanEck Vectors Pharmaceut.. 0.00 % 0.35 %

+0.31 (+0.44%)

USD0.23B
QLTA iShares Aaa - A Rated Cor.. 0.00 % 0.15 %

+0.02 (+0.04%)

USD1.37B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.04 (-0.53%)

USD1.42M
SPLV Invesco S&P 500 Low Volat.. 0.00 % 0.25 %

+0.08 (+0.13%)

USD7.75B
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.49 %

-0.15 (-0.02%)

USD0.03B
XPH SPDR S&P Pharmaceuticals .. 0.00 % 0.35 %

+0.14 (+0.29%)

USD0.28B
XRLV Invesco S&P 500 ex-Rate S.. 0.00 % 0.25 %

+0.17 (+0.36%)

USD0.05B
BVAL Brand Value ETF 0.00 % 0.65 %

N/A

USD9.33M
NUBD Nuveen ESG U.S. Aggregate.. 0.00 % 0.20 %

+0.02 (+0.07%)

USD0.22B
ULVM VictoryShares USAA MSCI U.. 0.00 % 0.20 %

+0.37 (+0.57%)

USD0.54B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

+0.18 (+0.72%)

USD0.02B
HONR InsightShares Patriotic E.. 0.00 % 0.65 %

N/A

USD1.34M
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.65 %

+0.08 (+0.70%)

USD0.15B
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.65 %

N/A

N/A
VMUS:XETRA VanEck Vectors ETFs N.V. .. 0.00 % 0.00 %

+0.41 (+0.98%)

USD9.02M

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.27% 44% F 40% F
Dividend Return 0.79% 33% F 43% F
Total Return 5.06% 44% F 40% F
Trailing 12 Months  
Capital Gain 5.81% 67% D+ 15% F
Dividend Return 3.08% 33% F 43% F
Total Return 8.88% 56% F 16% F
Trailing 5 Years  
Capital Gain -9.18% 22% F 21% F
Dividend Return 11.71% 11% F 39% F
Total Return 2.53% 11% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 2.52% 22% F 50% F
Dividend Return 2.95% 56% F 66% D
Total Return 5.47% 22% F 51% F
Risk Return Profile  
Volatility (Standard Deviation) 19.01% 33% F 55% F
Risk Adjusted Return 28.80% 11% F 45% F
Market Capitalization 142.79B 33% F 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 93.81 11% F 8% F
Price/Book Ratio 3.69 78% C+ 29% F
Price / Cash Flow Ratio 10.16 100% A+ 45% F
EV/EBITDA 21.98 56% F 28% F
Management Effectiveness  
Return on Equity -14.15% 11% F 18% F
Return on Invested Capital 0.06% 11% F 30% F
Return on Assets 3.93% 11% F 71% C-
Debt to Equity Ratio 127.80% 44% F 29% F
Technical Ratios  
Short Ratio 1.63 88% B+ 57% F
Short Percent 0.85% 50% F 86% B
Beta 0.62 44% F 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector